KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Shares Outstanding (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Shares Outstanding for 16 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 8.33% year-over-year to $1.3 billion, compared with a TTM value of $1.3 billion through Dec 2025, up 8.33%, and an annual FY2025 reading of $1.3 billion, up 8.33% over the prior year.
  • Shares Outstanding was $1.3 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $1.3 billion in the prior quarter.
  • Across five years, Shares Outstanding topped out at $1.3 billion in Q4 2025 and bottomed at $1.2 billion in Q4 2024.
  • Average Shares Outstanding over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2023.
  • The sharpest move saw Shares Outstanding dropped 2.2% in 2024, then increased 8.33% in 2025.
  • Year by year, Shares Outstanding stood at $1.2 billion in 2021, then increased by 0.66% to $1.2 billion in 2022, then grew by 0.82% to $1.2 billion in 2023, then decreased by 2.2% to $1.2 billion in 2024, then increased by 8.33% to $1.3 billion in 2025.
  • Business Quant data shows Shares Outstanding for TEVA at $1.3 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.3 billion in Q2 2025.